Sanofi Plots Cancer Comeback With First New Drug in Years
Sanofi was a spectator during the last wave of cancer breakthroughs. The French drugmaker is counting on its first new tumor drug in seven years to help make it a contender in the next one. A treatment Sanofi is developing with Regeneron Pharmaceuticals Inc. could go on sale by the end of the year, said Joanne Lager, head of oncology development at the Paris-based company.